Prevention and Treatment of Cardiovascular Disease in Patients with Chronic Kidney Disease: Patient-Oriented Research and Mentoring

项目摘要 超过10%的世界人口患有慢性肾脏疾病（CKD），并且心血管疾病是慢性肾脏疾病的主要病因。 发病和死亡的原因。大约50%的晚期CKD患者死于心血管疾病 疾病然而，只有有限的证据可以为预防和治疗的最佳策略提供信息。 心血管疾病在这个人群中。心血管疾病的病理学可能不同， 与一般人群相比，慢性肾病的发病率较高，心血管治疗可能具有不同的风险和益处。 关于使用药物预防或治疗CKD患者心血管疾病的指南通常 不清楚的或矛盾的。此K24应用程序的首要目标是解决证据中的主要差距 CKD患者的心血管疾病发展、预防和治疗， 初级调查员接受严格的培训和指导，以推动该领域的发展。的 候选人Morgan Grams博士，医学博士和博士，是一位肾脏病学家和流行病学家，具有临床研究方面的专业知识 方法和良好的成功指导记录。Grams博士的研究组合提供了充足的 数据和机会，以解决临床上重要的问题，在交叉的心血管疾病和 CKD，包括CKD心血管预后的分子基础以及安全性和有效性 批准的心血管治疗在肾功能范围内。K24可以让格拉姆博士 扩大她的指导，以确保下一代以患者为导向的研究人员能够利用 不断增长的医疗保健数据的可用性，以补充和加强临床前工作和临床 审判

PROJECT SUMMARY Over 10% of the world’s population has chronic kidney disease (CKD), and cardiovascular disease is a primary cause of morbidity and mortality. Approximately 50% of patients with advanced CKD die from cardiovascular disease. However, there is limited evidence to inform optimal strategies for prevention and treatment of cardiovascular disease in this population. The pathology of cardiovascular disease may differ in the presence of CKD compared to the general population, and cardiovascular therapy may have distinct risks and benefits. Guidelines on the use of medications to prevent or treat cardiovascular disease in persons with CKD are often unclear or conflicting. The overarching goal of this K24 application is to address major gaps in the evidence surrounding cardiovascular disease development, prevention, and treatment in patients with CKD, providing junior investigators with the rigorous training and mentorship needed in order to advance the field. The candidate, Dr. Morgan Grams, MD PhD, is a nephrologist and epidemiologist with expertise in clinical research methods and a strong track record of successful mentorship. Dr. Grams’s research portfolio provides ample data and opportunity to address clinically important questions at the intersection of cardiovascular disease and CKD, including the molecular basis of cardiovascular prognosis in CKD as well as the safety and effectiveness of approved cardiovascular therapy across the range of kidney function. The K24 will allow Dr. Grams to expand her mentoring to ensure the next generation of patient-oriented researchers are able to take advantage of the ever-growing availability of health care data to complement and enhance pre-clinical work and clinical trials.